옵션 체인은 다양한 행사가격과 만기일에 대한 Longeveron의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Longeveron에 대한 시장 심리를 평가합니다..

Longeveron (NASDAQ:LGVN) 주식, 옵션 체인

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

LGVN

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

각 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스의 하나인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 7월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 실적은 8월 1일을 기준으로 하며 배당금은 포함되지 않는다. 4월 검색결과는 추적되지 않았다.

단독: 7월 벤징가 프로에서 가장 많이 검색된 상위 20개 종목 - 테슬라, 엔비디아, CRWD 순위는?

ASNS

AVGO

DELL

FFIE

MLGO

RIVN

각 거래일에는 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 6월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 성과는 6월 30일 기준이며 배당금은 포함되어 있지 않다. 4월 검색결과는 추적되지 않았다.

단독: 6월 벤징가 프로에서 가장 많이 검색된 상위 10종목 - 엔비디아, 애플, 테슬라는 어디에?

Longeveron Inc

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and maintains $10 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

<p><a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_11132024_LGVN_Sorensen-pdf.pdf</a></p>


Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation

<p>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.44) by 22.73 percent. This is a 87.81 percent increase over losses of $(2.79) per share from the same period last year.  The company reported quarterly sales of $773.000 thousand which beat the analyst consensus estimate of $397.000 thousand by 94.71 percent.  This is a 415.33 percent increase over sales of $150.000 thousand the same period last year.</p>


Earnings

Earnings Beats

Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

<p>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) will release its quarterly earnings report on Tuesday, 2024-11-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Longeveron to report an <strong>earnings per share</strong> (EPS) of $-0.44.</p>
<p>Anticipation surrounds Longeveron's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.78, leading to a 5.75% drop in the share price on the subsequent day.</p>
<p>Here's a look at Longeveron's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.05</td>
<td>-2</td>
<td>-2.1</td>
<td>-2.2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.83</td>
<td>-1.61</td>
<td>-2.5</td>
<td>-2.8</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731341085_0.png" alt="eps graph" /></p>
<h3>Longeveron Share Price Analysis</h3>
<p>Shares of Longeveron were trading at $2.2 as of November 08. Over the last 52-week period, shares are down 87.71%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Longeveron</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Longeveron.</p>
<p>A total of 4 analyst ratings have been received for Longeveron, with the consensus rating being Buy. The average one-year price target stands at $9.0, suggesting a potential 309.09% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of  and Longeveron, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for  and Longeveron, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Longeveron</td>
<td>Buy</td>
<td>115.67%</td>
<td>$344K</td>
<td>-132.73%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Longeveron ranks at the bottom for Revenue Growth with a negative percentage. It also ranks at the bottom for Gross Profit with the lowest value. Additionally, it ranks at the bottom for Return on Equity with a negative percentage. Overall, Longeveron is positioned at the bottom compared to its peers across all metrics provided.</p>
<h3>Discovering Longeveron: A Closer Look</h3>
<p>Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.</p>
<h3>Financial Insights: Longeveron</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Longeveron's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>115.67%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Longeveron's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-2545.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Longeveron's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-132.73%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Longeveron's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-81.91%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Longeveron's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.12</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LGVN/earnings"><strong>To track all earnings releases for Longeveron visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Longeveron's Earnings Forecast

<p>In the last three months, 4 analysts have published ratings on Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Longeveron and provided 12-month price targets. The average target is $9.0, accompanied by a high estimate of $10.00 and a low estimate of $6.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.0%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730750458_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Longeveron by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Michael Okunewitch</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Longeveron. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Longeveron compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Longeveron's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Longeveron's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LGVN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Longeveron analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Longeveron</h2>
<p>Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.</p>
<h3>Longeveron's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Longeveron showcased positive performance, achieving a revenue growth rate of <strong>115.67%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2545.73%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Longeveron's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-132.73%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Longeveron's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-81.91%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Longeveron's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Longeveron Through Analyst Insights

Biotech

General

Longeveron Presents Lomecel-B Data For Mild Alzheimer's At CTAD24, Showing Potential Clinical And Biomarker Improvements Through MMP14 Inhibition

<p>Shares of <strong>LENZ Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) rose sharply in <a href="https://www.benzinga.com/quote/LENZ">today's pre-market trading</a>.</p>
<p>CORXEL and LENZ Therapeutics revealed topline data from China Phase 3 Presbyopia trial of LNZ100.</p>
<p>LENZ Therapeutics shares jumped 18% to $31.88 in the pre-market trading session.</p>
<p>Here are some other stocks moving in pre-market trading.</p>
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li><strong>Healthcare Triangle, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) rose 121% to $1.28 in pre-market trading. The Healthcare Triangle announced it acquired substantially all of the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies on Oct. 21.</li>
<li><strong>Pixie Dust Technologies, In</strong>c.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXDT#NASDAQ">PXDT</a>) gained 109% to $1.40 in pre-market trading. Pixie Dust Technologies shares dipped 36% on Friday after the company recently announced it will delist its ADR units from the Nasdaq Capital Market and submit a deregistration application with the SEC.</li>
<li><strong>Jet.AI In</strong>c. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares rose 24.6% to $0.0847 in pre-market trading after falling 16% on Friday. Jet.AI announced the pricing of $1.5 million registered direct offering of 15.6 million shares of common stock at a price of $0.096 per share.</li>
<li><strong>Top Wealth Group Holding Limited </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares surged 24.5% to $0.6720 in pre-market trading after dipping 96% on Friday.</li>
<li><strong>TC Biopharm (Holdings) Pl</strong>c (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares jumped 19.4% to $1.91 in pre-market trading after dipping 19% on Friday.</li>
<li><strong>Longeveron Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) climbed 19% to $2.63 in pre-market trading. Longeveron shared long-term data on transplant-free survival with Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) at the 51st Annual Meeting CHSS.</li>
<li><strong>Tarsus Pharmaceuticals, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) gained 15.5% to $45.50 in pre-market trading.</li>
<li><strong>ImmunityBio, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares rose 11.8% to $5.95 in pre-market trading after jumping 26% on Friday.</li>
<li><strong>ADS-TEC Energy PLC</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) shares gained 10.3% to $15.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li><strong>SMX (Security Matters) Public Limited Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dipped 30% to $0.9739 in pre-market trading after dipping 33% on Friday.</li>
<li><strong>Upexi, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares fell 21.8% to $6.33 in pre-market trading. Upexi shares jumped 170% on Friday after the company said it is currently reviewing trading activity to determine if recent activity involved possible stock manipulation.</li>
<li><strong>Monopar Therapeutics Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares fell 19% to $13.72 in pre-market trading after dipping 48% on Friday. The company recently entered into an agreement with Alexion, AstraZeneca Rare Disease, for an exclusive worldwide license to ALXN-1840 for Wilson disease.</li>
<li><strong>EON Resources Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) fell 16.8% to $1.04 in today's pre-market trading.</li>
<li><strong>ARB IOT Group Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) fell 16.6% to $0.57 in pre-market trading after jumping 107% on Friday.</li>
<li><strong>Jeffs&#8217; Brands Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) fell 16.5% to $0.2821 in pre-market trading after jumping 23% on Friday.</li>
<li><strong>Koninklijke Philips N.V.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 16.1% to $26.58 in pre-market trading after posting downbeat quarterly results.</li>
<li><strong>NWTN Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares declined 13.8% to $0.8090 in pre-market trading after jumping 62% on Friday.</li>
<li><strong>Indonesia Energy Corporation Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) shares fell 13% to $4.03 after gaining 7% on Friday.</li>
<li><strong>Tevogen Bio Holdings Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) fell 9.5% to $2.76 in pre-market trading. Tevogen Bio issued additional guidance on introduction of T Cell therapy for oncology and specialty care therapeutic areas.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/10/41545103/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></strong></li>
</ul>


Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LENZ

MNPR

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

<ul>
<li>Oral presentation highlights findings that patients treated with Lomecel-BTM&nbsp;in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of&nbsp;100%&nbsp;with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed&nbsp;83%&nbsp;survival, with a&nbsp;5.2%&nbsp;heart transplantation rate</li>
<li>ELPIS I met its primary endpoint of safety through 1-year post-treatment, with&nbsp;100%&nbsp;survival rate,&nbsp;100%&nbsp;transplant-free and patients maintained expected rate of growth one year after treatment</li>
<li>Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation</li>
<li>ELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-BTM&nbsp;as a potential adjunct therapy for HLHS versus standard of care alone</li>
</ul>


Reported Earlier, Longeveron Shares Long-term Data On Transplant-free Survival with Lomecel-B In Hypoplastic Left Heart Syndrome (HLHS) At the 51st Annual Meeting CHSS

<p><a href="https://www.globenewswire.com/Tracker?data=p2ZZV-CeoiZqcwQi6diNtLUJvX7tLxeaFYKWkdKmh15GIz7-tuTKp2LR7B6nqdKI502nR8gibPU2uLrCUsXkNA==">Longeveron Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clinical trial were featured in an oral presentation at the <a href="https://www.globenewswire.com/Tracker?data=zqLFI_yltO4_MViE3EX9a0mZGiNtIc5Ds70F3WczLQZTlzsuln0HvMmAfIu9kaQ31Pwde5-y6SpNYO_6laBrKnXoKqT5A6w4IB6dgvZDAKFBt8y5FoN1STXqZSRcOuzy">Congenital Heart Surgeons' Society (CHSS)</a> <a href="https://www.globenewswire.com/Tracker?data=OG_dIuUy_1lvqGh8D8nttf8FiEP-xm6XpA5sysVdkPCmHOxp-P7C9icDVz5lZ56pPzeboToLVxSI5hjqVPnl41MCMJPz0gvajTfzPofo_WU=">51st Annual Meeting</a> taking place October 27-28, 2024 in Chicago, Illinois.</p>
<ul>
<li>Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2% heart transplantation rate</li>
<li>ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatment</li>
<li>Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation</li>
<li>ELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-BTM as a potential adjunct therapy for HLHS versus standard of care alone</li>
</ul>


Longeveron Said ELPIS I Met Its Primary Endpoint Of Safety Through 1-year Post-treatment, With 100% Survival Rate

Events

Longeveron Announces Late Breaking Poster Presentation At Clinical Trials On Alzheimer's Disease Conference On Oct. 29

Longeveron Lomecel-B 5-Year Long-Term Transplant-Free Survival Data In HLHS Selected For Oral Presentation At Congenital Heart Surgeons' Society 51st Annual Meeting

<ul>
<li><i>On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approval</i></li>
<li><i>Alignment with FDA on ELPIS II primary and secondary endpoints</i>
<ul>
<li><i>Alignment with FDA on CMC and Potency Assay plan and requirements</i><br />&nbsp;</li>
</ul>
</li>
</ul>


Longeveron Announces Type C Meeting With U.S. FDA Regarding Pathway to BLA for Lomecel-B In Hypoplastic Left Heart Syndrome

<p>In the preceding three months, 4 analysts have released ratings for Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.0, along with a high estimate of $10.00 and a low estimate of $6.00. This current average has decreased by 23.4% from the previous average price target of $11.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724770847_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Longeveron among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Okunewitch</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Longeveron. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Longeveron compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Longeveron's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Longeveron's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LGVN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Longeveron analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Longeveron: A Closer Look</h2>
<p>Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.</p>
<h3>Longeveron's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Longeveron displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>115.67%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Longeveron's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-2545.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Longeveron's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-132.73%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-81.91%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.12</strong>, Longeveron adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 4 Analysts Discuss Longeveron Stock

<p>Maxim Group  analyst Michael Okunewitch   maintains Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and lowers the price target from $15 to $6.</p>


Maxim Group Maintains Buy on Longeveron, Lowers Price Target to $6

Longeveron To Participate In H.C. Wainwright 26th Annual Global Investment Conference On September 10, 2024; Webcast Available On Company Website

<p>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(1.83) per share. This is a 31.46 percent increase over losses of $(2.67) per share from the same period last year.  The company reported quarterly sales of $468.00 thousand which missed the analyst consensus estimate of $525.00 thousand by 10.86 percent.  This is a 115.67 percent increase over sales of $217.00 thousand the same period last year.</p>


Earnings Misses

Longeveron Q2 2024 GAAP EPS $(1.83) Up From $(2.67) YoY, Sales $468.00K Miss $525.00K Estimate

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Longeveron (LGVN – Research Report) today and set a price target of $10.00. Ram Se...

Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress

Longeveron (LGVN) announced that its positive long-term transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clin...

Longeveron presents Lomecel-B long-term transplant-free survival data in HLHS

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Longeveron (LGVN – Research Report), retaining the price target of $10.00. Ram ...

Promising Prospects for Lomecel-B: A Buy Recommendation Based on Positive Clinical Data and Regulatory Potential

Longeveron (LGVN) announced that it has appointed Devin Blass as Chief Technology Officer, CTO, and Senior Vice President of Chemistry, Manufacturi...

Longeveron appoints Blass as Chief Technology Officer

Reports Q3 revenue $210, consensus $400k ."In the third quarter, we continued to advance the development of our investigational cellular therapy ca...

Longeveron reports Q3 EPS (34c), consensus (44c)

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Longeveron reports Q3 results

Longeveron (LGVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. W...

Longeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial Position

Roth MKM initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target Published first on TheFly – the ultimate source for real-ti...

Longeveron initiated with a Buy at Roth MKM

Roth MKM last night initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target The firm says its investment thesis is driven by...

Screenshot 2024-11-15 at 7.50.34 PM

BCLI

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Health Care

Press Releases

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Management

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Comments

Longeveron

Longeveron (LGVN) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌